The US now has over a 1 million COVID cases. ARDS and lung related problems will be an ongoing market for this alone. Hospitalisations will create a massive burden on the US Hospitals and they need to tackle this ASAP.
Mesoblast is in a very good position to treat this problem.
Melbourne, Australia; Friday April 17, 2020 and New York, USA; April 16, 2020: Mesoblast Limited (ASX:MSB; Nasdaq: MESO) today announced that results using its allogeneic mesenchymal stem cell product candidate remestemcel-L in patients with inflammatory lung disease have been selected for oral presentation at the 2020 International Society of Cell and Gene Therapy (ISCT) annual meeting being held May 28-29, 2020
http://investorsmedia.mesoblast.com/static-files/f7c1b407-e130-4190-9283-620e0fe621a5
Ann: Appendix 4C - quarterly, page-60
-
- There are more pages in this discussion • 144 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
96.0¢ |
Change
0.010(1.05%) |
Mkt cap ! $1.096B | |||
| Open | High | Low | Value | Volume |
| 94.5¢ | 97.5¢ | 94.0¢ | $2.076M | 2.161M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 162826 | 96.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 97.0¢ | 28820 | 3 |
View Market Depth
| Last trade - 16.10pm 21/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |